Erste Asset Management Gmb H Vaxcyte, Inc. Transaction History

Erste Asset Management Gmb H

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Nov 26, 2024	BUY	$45.35 - $63.41 $208,610 - $291,686	4,600 Added 15.86%	33,600 $2.13 Billion
Q1 2023 Nov 26, 2024	BUY	$36.27 - $47.2 $536,796 - $698,560	14,800 Added 104.23%	29,000 $1.05 Billion
Q4 2022 Nov 26, 2024	BUY	$20.58 - $47.95 $304,584 - $709,660	14,800 Added 104.23%	29,000 $1.38 Billion
Q3 2022 Nov 26, 2024	BUY	$21.69 - $28.53 $307,998 - $405,126	14,200 New	14,200 $352 Million
Q2 2022 Nov 26, 2024	BUY	$17.68 - $26.58 $251,056 - $377,436	14,200 New	14,200 $294 Million
Q4 2021 Nov 22, 2024	BUY	$19.32 - $26.45 $274,344 - $375,590	14,200 New	14,200 $341 Million
Q4 2020 Nov 22, 2024	BUY	$26.57 - $51.74 $377,294 - $734,708	14,200 New	14,200 $398 Million

358

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.34B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.